Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
Nanobiotix ( (NBTX) ) has provided an update.
Nanobiotix announced its updated number of shares outstanding and voting rights as of November 30, 2024, with 47,426,851 shares and 49,202,229 total theoretical voting rights. This disclosure is part of compliance with French financial regulations and ensures transparency for shareholders and stakeholders, reflecting the company’s commitment to regulatory standards.
More about Nanobiotix
Nanobiotix is a late-stage clinical biotechnology company based in Paris, France, focused on pioneering disruptive, physics-based therapeutic approaches. The company, founded in 2003, is listed on Euronext Paris and the Nasdaq Global Select Market and owns over 25 patent families across three nanotechnology platforms with applications in oncology, bioavailability and biodistribution, and central nervous system disorders.
YTD Price Performance: -54.81%
Average Trading Volume: 19,835
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $158.5M
See more insights into NBTX stock on TipRanks’ Stock Analysis page.
